Filing Details

Accession Number:
0001214659-21-008130
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-03 19:45:43
Reporting Period:
2021-07-30
Accepted Time:
2021-08-03 19:45:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1677077 Alzamend Neuro Inc. ALZN () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1212502 Iii C Milton Ault 3802 Spectrum Boulevard, Suite 112C
Tampa FL 33612
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-30 5,000 $4.57 5,346,555 No 4 P Indirect By Digital Power Lending, LLC
Common Stock Acquisiton 2021-07-30 1,333,333 $1.50 6,679,888 No 4 P Indirect By Digital Power Lending, LLC
Common Stock Acquisiton 2021-08-02 1,500 $4.56 6,681,388 No 4 P Indirect By Digital Power Lending, LLC
Common Stock Acquisiton 2021-08-03 500 $4.35 6,681,888 No 4 P Indirect By Digital Power Lending, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Digital Power Lending, LLC
No 4 P Indirect By Digital Power Lending, LLC
No 4 P Indirect By Digital Power Lending, LLC
No 4 P Indirect By Digital Power Lending, LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Purchase Warrants Acquisiton 2021-07-30 666,667 $0.00 666,667 $1.50
Common Stock Call Option (right to buy) Acquisiton 2021-07-30 500 $10.51 50,000 $10.00
Common Stock Call Option (right to buy) Acquisiton 2021-07-30 20 $155.51 2,000 $5.00
Common Stock Call Option (right to buy) Acquisiton 2021-07-30 10 $80.51 1,000 $10.00
Common Stock Call Option (right to buy) Acquisiton 2021-07-30 10 $95.51 1,000 $7.50
Common Stock Call Option (right to buy) Acquisiton 2021-08-03 10 $70.51 1,000 $10.00
Common Stock Call Option (right to buy) Acquisiton 2021-08-03 10 $228.51 1,000 $2.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
666,667 2026-07-29 No 4 P Indirect
500 2021-08-20 No 4 P Indirect
50 2022-02-18 No 4 P Indirect
30 2022-02-18 No 4 P Indirect
30 2022-02-18 No 4 P Indirect
40 2022-02-18 No 4 P Indirect
10 2022-02-18 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 15,000,000 Indirect By Ault Life Sciences, Inc.
Common Stock 10,000,000 Indirect By Ault Life Sciences Fund, LLC
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Common Stock Purchase Warrants $1.50 2026-03-08 1,333,333 1,333,333 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2026-03-08 1,333,333 1,333,333 Indirect
Footnotes
  1. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.5687. The range of purchase prices on the transaction date was $4.45 to $4.71 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
  2. Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
  3. DPL purchased 1,333,333 shares of the Issuer's common stock and warrants to purchase 666,667 shares of the Issuer's common stock with an exercise price of $3.00 per share, pursuant to a securities purchase agreement dated March 9, 2021, entered into by and between DPL and the Issuer.
  4. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.5633. The range of purchase prices on the transaction date was $4.50 to $4.595 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
  5. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
  6. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
  7. These warrants are exercisable, however, they are not deemed to be beneficially owned since they contain a beneficial ownership blocker provision preventing exercise if the exercise would result in the holder beneficially owning in excess of 4.99% of the Issuer's common stock.
  8. The security listed is an exchange-traded option contract. Exchange-traded options are immediately exercisable and remain exercisable until expiration.